The US Department of Defense removed its clinical protocol on military hormone testing on 3 September 2026, less than 24 hours after publishing the document online. The memorandum, titled "Clinical Guidance for Health and Human Performance Optimization", was published on 2 September 2026 on the official websites of the Pentagon and the Defense Health Agency. The policy had been designated to take effect immediately, but by Thursday morning both links were disabled with "Page Not Found" errors. An accompanying statement from Pentagon spokesperson Sean Parnell was also removed from the official website.

A defense official confirmed that the document had been pulled offline to incorporate revisions before a final version is reissued.

“The draft published on September 2, 2026, has been temporarily rescinded to allow for updates.”

Testing protocols for active troops and reservists

The retracted guidance set standardized screening procedures covering both active-duty personnel and reservists during regular annual medical evaluations. Under the protocol, male service members aged 30 and older were required to complete an initial screening questionnaire, which could lead to laboratory blood tests to measure total testosterone levels. Service members under 30 years old were not subject to mandatory blood draws but could request testing on a voluntary basis or receive clinical referrals if symptoms appeared.

For female service members, the framework did not mandate routine hormone blood testing. Instead, female personnel aged 35 and older were to be evaluated through questionnaires for symptoms of hormonal dysregulation during routine physicals. Testosterone therapy for women was restricted to specific conditions with established clinical evidence, such as hypoactive sexual desire disorder.

Leadership rationale and treatment framework

Defense Secretary Pete Hegseth announced the mandatory screening program in July 2026, framing hormone monitoring as a method to support physical capability and long-term health across the ranks. The Department of Defense characterized testosterone as a key biological indicator connected to physical strength, bone mineral density, aerobic fitness, cardiovascular health, and depressive symptoms. Department officials noted that prolonged operational stress, demanding deployment cycles, sleep disruption, and physical trauma in military service can suppress natural hormone production.

Under the published guidelines, personnel diagnosed with hypogonadism could access hormone replacement therapy, though accepting medical treatment remained voluntary. Hegseth defended the initiative in July by stating that testing aimed to restore natural physiological baselines and maintain the biological foundation required for military operations rather than provide artificial performance enhancements.

Medical skepticism and upcoming FDA review

The screening mandate has faced scrutiny from physicians who questioned the scientific grounding of population-wide hormone testing. Medical experts raised concerns that routine screening could lead to unnecessary or potentially harmful testosterone therapies, noting that little clinical data demonstrates that broad testing improves military operational readiness.

The US Food and Drug Administration scheduled an advisory meeting of medical experts in mid-September 2026 to evaluate the clinical use and safety of testosterone products. Defense officials stated that while the guidance undergoes revision, interim screening instructions remain in effect, with the final version of the clinical guidance expected to be released soon.